Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Valk AM, Keijser JBD, van Dam KPJ, Stalman EW, Wieske L, Steenhuis M, Kummer LYL, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Horváth B, Hijnen DJ, Schreurs CRG, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Keijzer S, Derksen NIL, van Deelen M, van Mierlo G, Kuijpers TW, Eftimov F, van Ham SM, Ten Brinke A, Rispens T; T2B! Immunity against SARS-CoV-2 study group. Valk AM, et al. Among authors: wolbink gj. Allergy. 2024 Mar 4. doi: 10.1111/all.16089. Online ahead of print. Allergy. 2024. PMID: 38439527
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.
Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T. Berkhout LC, et al. Among authors: wolbink gj. Sci Transl Med. 2019 Jan 30;11(477):eaat3356. doi: 10.1126/scitranslmed.aat3356. Sci Transl Med. 2019. PMID: 30700574 Clinical Trial.
Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.
Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A. Hernández-Breijo B, et al. Among authors: wolbink gj. Arthritis Res Ther. 2019 Feb 20;21(1):66. doi: 10.1186/s13075-019-1849-3. Arthritis Res Ther. 2019. PMID: 30786913 Free PMC article.
The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.
Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T. Berkhout LC, et al. Among authors: wolbink gj. Clin Exp Rheumatol. 2020 Mar-Apr;38(2):306-313. doi: 10.55563/clinexprheumatol/nlr4r8. Epub 2019 Aug 30. Clin Exp Rheumatol. 2020. PMID: 31498069 Free article.
Immunogenicity of TNF-Inhibitors.
Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Atiqi S, et al. Among authors: wolbink gj. Front Immunol. 2020 Feb 26;11:312. doi: 10.3389/fimmu.2020.00312. eCollection 2020. Front Immunol. 2020. PMID: 32174918 Free PMC article. Review.
Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses.
Unger PA, Lighaam LC, Vermeulen E, Kruithof S, Makuch M, Culver EL, van Bruggen R, Remmerswaal EBM, Ten Berge IJM, Emmens RW, Niessen HWM, Barnes E, Wolbink GJ, van Ham SM, Rispens T. Unger PA, et al. Among authors: wolbink gj. Eur J Immunol. 2020 Aug;50(8):1113-1125. doi: 10.1002/eji.201948454. Epub 2020 May 25. Eur J Immunol. 2020. PMID: 32289181 Free article.
142 results